IL240701B - Kntc2 peptides and vaccines containing the same - Google Patents

Kntc2 peptides and vaccines containing the same

Info

Publication number
IL240701B
IL240701B IL240701A IL24070115A IL240701B IL 240701 B IL240701 B IL 240701B IL 240701 A IL240701 A IL 240701A IL 24070115 A IL24070115 A IL 24070115A IL 240701 B IL240701 B IL 240701B
Authority
IL
Israel
Prior art keywords
components containing
kntc2
peptides
kntc2 peptides
components
Prior art date
Application number
IL240701A
Other languages
English (en)
Hebrew (he)
Other versions
IL240701A0 (en
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL240701A0 publication Critical patent/IL240701A0/en
Publication of IL240701B publication Critical patent/IL240701B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
IL240701A 2013-03-12 2015-08-20 Kntc2 peptides and vaccines containing the same IL240701B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777334P 2013-03-12 2013-03-12
PCT/JP2014/001350 WO2014141683A1 (en) 2013-03-12 2014-03-11 Kntc2 peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
IL240701A0 IL240701A0 (en) 2015-10-29
IL240701B true IL240701B (en) 2022-02-01

Family

ID=51536362

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240701A IL240701B (en) 2013-03-12 2015-08-20 Kntc2 peptides and vaccines containing the same

Country Status (17)

Country Link
US (1) US9597382B2 (enExample)
EP (1) EP2970944B1 (enExample)
JP (1) JP6295491B2 (enExample)
KR (1) KR102213574B1 (enExample)
CN (1) CN105164256B (enExample)
AR (1) AR095386A1 (enExample)
AU (1) AU2014232630B2 (enExample)
BR (1) BR112015021828A2 (enExample)
CA (1) CA2903139C (enExample)
DK (1) DK2970944T3 (enExample)
ES (1) ES2739693T3 (enExample)
IL (1) IL240701B (enExample)
MX (1) MX366365B (enExample)
RU (1) RU2671395C2 (enExample)
SG (2) SG11201507236XA (enExample)
TW (1) TWI658049B (enExample)
WO (1) WO2014141683A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2490025A3 (en) 2007-03-27 2012-11-28 Immunovia AB Method, array and use thereof
WO2016127249A1 (en) * 2015-02-09 2016-08-18 Université de Montréal Novel minor histocompatibility antigens and uses thereof
ES2960205T3 (es) * 2015-06-16 2024-03-01 Fond Citta Della Speranza Onlus Vesículas extracelulares derivadas de células del linaje osteoblástico para uso terapéutico y diagnóstico
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
HUE058717T2 (hu) 2017-01-25 2022-09-28 Ose Immunotherapeutics Eljárás egy stabil emulzió elõállítására peptid szállításához
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
WO2022076788A1 (en) * 2020-10-09 2022-04-14 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
AU6795898A (en) 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1375515A3 (en) * 1997-10-07 2004-04-21 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use thereof
ATE375362T1 (de) 1998-06-25 2007-10-15 Kyogo Itoh Von cyclophilin b abstammende tumorantigen- peptide
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20040224408A1 (en) 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
EP1572118A4 (en) 2002-12-20 2010-07-14 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
US20050100933A1 (en) 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005029067A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
EP2481802B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
EP1756147A2 (en) 2004-06-01 2007-02-28 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8349555B2 (en) * 2005-03-16 2013-01-08 Gennadi V. Glinsky Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007013480A2 (en) 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
US7507536B2 (en) * 2005-10-07 2009-03-24 The Johns Hopkins University Methylation markers for diagnosis and treatment of ovarian cancer
US20090263832A1 (en) 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
JP5576610B2 (ja) * 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
ES2487637T3 (es) 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
CA2696591C (en) 2007-08-20 2016-10-11 Oncotherapy Science, Inc. Cdh3 peptide and medicinal agent comprising the same
US9273100B2 (en) * 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
WO2009099580A2 (en) * 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20100281003A1 (en) * 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
US20120264634A1 (en) 2009-09-29 2012-10-18 Protagen Aktiengesellschaft Marker Sequences for Pancreatic Cancer Diseases, Pancreatic Carcinoma and Use Thereof
CA2907181C (en) * 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP3008204B1 (en) * 2013-06-10 2024-03-13 Iogenetics, LLC. Mathematical processes for determination of peptidase cleavage

Also Published As

Publication number Publication date
EP2970944A1 (en) 2016-01-20
DK2970944T3 (da) 2019-07-22
JP2016511221A (ja) 2016-04-14
AR095386A1 (es) 2015-10-14
US9597382B2 (en) 2017-03-21
JP6295491B2 (ja) 2018-03-20
SG10201707316WA (en) 2017-10-30
CA2903139C (en) 2022-07-26
EP2970944A4 (en) 2017-04-19
RU2015143164A (ru) 2017-04-13
BR112015021828A2 (pt) 2017-08-29
HK1214838A1 (en) 2016-08-05
TWI658049B (zh) 2019-05-01
US20160008445A1 (en) 2016-01-14
AU2014232630B2 (en) 2020-07-09
IL240701A0 (en) 2015-10-29
WO2014141683A1 (en) 2014-09-18
MX2015012012A (es) 2016-04-07
KR20150126390A (ko) 2015-11-11
MX366365B (es) 2019-07-05
CN105164256A (zh) 2015-12-16
RU2671395C2 (ru) 2018-10-30
AU2014232630A1 (en) 2015-09-17
TW201443077A (zh) 2014-11-16
EP2970944B1 (en) 2019-05-08
ES2739693T3 (es) 2020-02-03
SG11201507236XA (en) 2015-10-29
CN105164256B (zh) 2018-10-19
CA2903139A1 (en) 2014-09-18
KR102213574B1 (ko) 2021-02-09

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
DK2951203T3 (da) Heterodimere proteiner
DK3033102T3 (da) Peptidkonjugerede partikler
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
CL2015003031A1 (es) Compuesto peptídico
EP2949343A4 (en) THREE-TONE CONNEXONE AND USE THEREOF
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
PL2970267T6 (pl) Modulatory P2X7
ZA201505966B (en) Peptides and compositions
HRP20181213T1 (hr) Peptidna smjesa
DK3041857T3 (da) Protein a-kromatografi
EP2970569A4 (en) PERSISTENT CARBENE AND COMPOSITIONS WITH IT
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
IL240701B (en) Kntc2 peptides and vaccines containing the same
LT3035885T (lt) Inhaliatorius
HRP20180452T1 (hr) Peptidi
DK3035886T3 (da) Inhalator
LT3035887T (lt) Inhaliatorius
EP3047192A4 (en) LOCKABLE LOCATED CONNECTOR
FR3007291B1 (fr) Composition cicatrisante et utlisation
FR3014440B1 (fr) Polypeptides entomotoxiques
PL2956129T3 (pl) Kompozycje farmaceutyczne zawierające deksketoprofen i tramadol
EP3006564A4 (en) NEW PEPTIDE AND ITS USE